Table 2 Baseline characteristics
From: Effects of sitagliptin beyond glycemic control: focus on quality of life
Enrolled subjects | Evaluated subjects | |
|---|---|---|
(n = 207) | (n = 188) | |
Age (years) | 66.5 ± 12.8 | 66.9 ± 12.6 |
Gender | Male: 50% (n = 103), | Male: 48% (n = 91), |
Female: 50% (n = 104) | Female: 52% (n = 97) | |
BMI | 25.0 ± 4.4 kg/m2 | 25.0 ± 4.4 kg/m2 |
Waist circumference | 89.4 ± 12.8 cm | 89.0 ± 12.8 cm |
Obesity (BMI > 25) | 51% | 50% |
Duration of DM (years) | 6.8 ± 6.5 | 6.9 ± 6.6 |
Smoking status | Smoker: 24% | Smoker: 23% |
Past smoker: 13% | Past smoker: 13% | |
Never: 63% | Never: 63% | |
Alcohol consumption | Yes: 30% | Yes: 29%, |
Complications | HT: 67%, DL: 55%, HUA: 7%, | HT: 65%, DL: 55%, |
Arrhythmia: 5%, CKD 43% | HUA: 6%, Arrhythmia: 5%, | |
CKD 43% | ||
Use of sitagliptin | New: 35% | New: 35% |
Added: 45%, Changed: 20% | Added 45%, Changed 20% | |
Combined drugs | SU: 49%, BG: 20%, TZD: 28%, | SU: 48%, BG: 22%, |
Glinide: 2%, α-GI: 7% | TZD: 28%, Glinide: 2%, α-GI: 7% |